Alpine Immune Sciences, Inc. (ALPN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Seattle, WA, United States. The current CEO is Mitchell H. Gold.
ALPN has IPO date of 2015-06-17, 142 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $4.46B.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer, autoimmune disorders, and inflammatory diseases. The company's pipeline includes ALPN-101, an ICOS/CD28 antagonist for autoimmune and inflammatory conditions; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for cancer treatment; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated diseases. Alpine has established strategic collaborations with AbbVie Ireland for ALPN-101 development and with Adaptimmune Therapeutics for next-generation SPEAR T cell products. Founded in 2007 and headquartered in Seattle, Washington, the company leverages its immunotherapy expertise to address significant unmet medical needs across multiple therapeutic areas.
